Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 20, 2020 - Issue 4
Submit an article Journal homepage
239
Views
7
CrossRef citations to date
0
Altmetric
Original Research

Appraisal of cancer drugs: a comparison of the French health technology assessment with value frameworks of two oncology societies

J. Lia Clinical Epidemiology Unit, Greater Paris University Hospitals (AP-HP), Paris, France;b Judge Business School, University of Cambridge, Cambridge, UK;c Faculty of Medicine, Paris XII University, Créteil, FranceCorrespondence[email protected]
View further author information
,
A. Vivota Clinical Epidemiology Unit, Greater Paris University Hospitals (AP-HP), Paris, France;d UMR1153 Epidemiology and Statistics Sorbonne Paris Cité Research Center (CRESS), INSERM, University Paris Descartes, Paris, FranceView further author information
,
L. Altere Department is Oncology Business Unit, LILLY FRANCE, Neuilly-sur-Seine, FranceView further author information
&
I. Durand-Zaleskif URC Eco IdF, Greater Paris University Hospitals (AP-HP), Paris, France;c Faculty of Medicine, Paris XII University, Créteil, FranceView further author information
Pages 405-409 | Received 31 Mar 2019, Accepted 20 Jun 2019, Published online: 26 Jun 2019

References

  • Schnipper LE, Davidson NE, Wollins DS, et al. Updating the American society of clinical oncology value framework: revisions and reflections in response to comments received. J Clin Oncol. 2016;34:2925–2934.
  • Cherny NI, Sullivan R, Dafni U, et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European society for medical oncology magnitude of clinical benefit scale (ESMO-MCBS). Ann Oncol. 2015;26:1547–1573.
  • Zafar SY, Abernethy AP. Financial toxicity, Part I: a new name for a growing problem. Oncology (Williston Park, N.Y.). 2013;27:80–81. 149.
  • Bentley TGK, Cohen JT, Elkin EB, et al. Validity and reliability of value assessment frameworks for new cancer drugs. Value Health. 2017;20:200–205.
  • Chouaid C, Borget I, Braun E, et al. French health technology assessment of antineoplastic drugs indicated in the treatment of solid tumours: perspective for future trends. Target Oncol. 2016;11:515–534.
  • Oudard S, Courbon F. Controversies and consensus in the innovation access for cancer therapy in the European countries: on the subject of metastatic prostate cancer. Ann Oncol. 2017;28:421–426.
  • Akehurst RL, Abadie E, Renaudin N, et al. Variation in health technology assessment and reimbursement processes in Europe. Value Health. 2017;20:67–76.
  • Pujolras LM, Cairns J. Why do some countries approve a cancer drug and others don’t?. J Cancer Policy. 2015;4:21–25.
  • Kanavos P, Nicod E, van Den Aardweg S, et al. The impact of health technology assessments: an international comparison. Euro Obs. 2010;12:1–7.
  • Aggarwal A, Fojo T, Chamberlain C, et al. Do patient access schemes for high-cost cancer drugs deliver value to society?-lessons from the NHS Cancer Drugs Fund. Ann Oncol. 2017;28:1738–1750.
  • Vivot A, Jacot J, Zeitoun J-D, et al. Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000–2015. Ann Oncol. 2017;28:1111–1116.
  • Fojo T, Mailankody S, Lo A. Unintended consequences of expensive cancer therapeutics—the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the John Conley Lecture. JAMA Otolaryngol Head Neck Surg. 2014;140:1225–1236.
  • Prasad V, McCabe C, Mailankody S. Low-value approvals and high prices might incentivize ineffective drug development. Nat Rev Clin Oncol. 2018;15:399–400.
  • Drugs@FDA: FDA Approved Drug Products [Internet]. [ cited 2018 May 17]. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm.
  • Del Paggio JC, Sullivan R, Schrag D, et al. Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks. Lancet Oncol. 2017;18:887–894.
  • Haute Autorité de Santé - TAFINLAR (dabrafenib), inhibiteur de tyrosine kinase [Internet]. [ cited 2018 May 11]. Available from: https://www.has-sante.fr/portail/jcms/c_1742463/fr/tafinlar-dabrafenib-inhibiteur-de-tyrosine-kinase.
  • Wild C, Grössmann N, Bonanno PV, et al. Utilisation of the ESMO-MCBS in practice of HTA. Ann Oncol. 2016;27:2134–2136.
  • Grande M, Fernandez J, Dahmani B, et al. 1436O_PRHow to assess a cancer therapy? Feedback from the French HTA body on the ESMO-MCBS. Ann Oncol. Internet]. 2017 cited 2018 May 17; 28. Available from: https://academic.oup.com/annonc/article/28/suppl_5/mdx440.064/4109976
  • Banzi R, Gerardi C, Bertele’ V, et al. Approvals of drugs with uncertain benefit-risk profiles in Europe. Eur J Intern Med. 2015;26:572–584.
  • Booth CM, Del Paggio JC. Approvals in 2016: questioning the clinical benefit of anticancer therapies. Nat Rev Clin Oncol. 2017;14:135–136.
  • Grössmann N, Del Paggio JC, Wolf S, et al. Five years of EMA-approved systemic cancer therapies for solid tumours-a comparison of two thresholds for meaningful clinical benefit. Eur J Cancer. 2017;82:66–71.
  • Gonçalves A, Maraninchi D, Vernant J-P. Challenging the soaring price of cancer medicines: a call for equity and transparency. Ann Oncol. 2016;27:1812–1813.
  • Cherny NI, Dafni U, Bogaerts J, et al. ESMO-magnitude of clinical benefit scale version 1.1. Ann. Oncol. 2017;28:2340–2366.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.